Abstract 925P
Background
Response to immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) varies among patients and depends on lesion features. This study evaluates the CD8 validated radiomics signature (RS) on the metastasis of RM-HNSCC patients to predict patient outcomes to nivolumab.
Methods
This study involved patients from the multi-institutional TOPNIVO phase II study (NCT03226756). At least 5 lesions per organ from each patient were delineated from baseline contrast enhanced CT scans. Features were extracted with the LIFEX software (IMIV/CEA, Orsay, France) and the RS was applied. Pre-treatment biopsies were used to quantify CD8 T-cells concentration (CD8C). The prognostic value of the CD8C and the minimum RS (mRS) were assessed, with values below the median classified as cold tumors.
Results
From 330 patients, 275 were eligible for the radiomics project, totaling 1371 lesions. CD8C was quantified from 133 patients providing a pre-treatment biopsy. CD8C was associated with PFS (HR=0.69, [0.49-0.69], P-value=0.042) and OS (HR=0.58, [0.40-0.84], P-value=0.004). The mRS was associated with OS (HR=0.70, [0.54-0.90], P-value=0.006). CD8C and mRS were independently associated with OS (HR=0.60, [0.41-0.88], P-value=0.009; HR=0.52, [0.34-0.77], P-value=0.001, multivariate analysis Table). Table: 925P
| Overall survival (HR [95%CI]) | P-value | Progression free survival (HR [95%CI]) | P-value | |
Age: ≥ 60 (vs ConclusionsThe least infiltrated lesion indicated by the mRS from metastatic lesions provide prognostic value in RM-HNSCC patients. This score could offer a valuable tool for clinicians to individualize management of RM-HNSCC under nivolumab. Clinical trial identificationNCT03226756. Editorial acknowledgementLegal entity responsible for the studyInstitut Gustave Roussy. FundingFondation ARC. DisclosureC. Even: Financial Interests, Personal, Advisory Board: BMS, MSD, Innate Pharma, Merck Serono; Financial Interests, Institutional, Advisory Board: F Star Therapeutics, Novartis, Elevar, BICARA, PDS Biotechnology, GSK, Merus; Financial Interests, Institutional, Local PI: BMS, AstraZeneca, ISA pharmaceutics, MSD, Debiopharma, Ayala, Gilead, GSK, Beigene, Takeda, Genmab, Seagen, Nykode; Financial Interests, Institutional, Coordinating PI: BMS, Novartis, sanofi. Y. Tao: Financial Interests, Institutional, Advisory Board: MSD, Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding: Onxeo, Merck; Financial Interests, Personal and Institutional, Advisory Board: Seagen. G. Lefebvre: Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Merck. A. Daste: Financial Interests, Personal and Institutional, Expert Testimony: Merck; Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb, Amgen; Financial Interests, Personal and Institutional, Funding: Merck. E.B. Saada: Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Invited Speaker: Merck Serono, MSD; Financial Interests, Coordinating PI: Novartis; Financial Interests, Institutional, Coordinating PI: Roche. J. Fayette: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Innate Pharma, Merck, Serono, Roche, Pfizer, Hookipa; Non-Financial Interests, Principal Investigator: AstraZeneca, MSD, Pfizer, Meru, Calliditas, Isa. P. Blanchard: Financial Interests, Institutional, Invited Speaker: Ipsen, Sanofi Aventis, Janssen, MSD; Financial Interests, Personal, Invited Speaker, advisory board and speaker at conferences: Bayer; Financial Interests, Institutional, Advisory Board: Becton Dickinson; Financial Interests, Institutional, Full or part-time Employment, Editor in Chief - Clinical and Translational Radiation Oncology: ESTRO. M. Classe: Financial Interests, Personal and Institutional, Member: Sanofi. A. Auperin: Financial Interests, Personal, Advisory Board: MSD. E. Deutsch: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb; Financial Interests, Personal, Funding: MSD, AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co.KG; Financial Interests, Personal and Institutional, Advisory Board: Merck. All other authors have declared no conflicts of interest. Resources from the same session1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapyPresenter: Yi Hu Session: Poster session 03 Resources: Abstract 1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritisPresenter: Michel Obeid Session: Poster session 03 1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter studyPresenter: Danielle Delombaerde Session: Poster session 03 1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective studyPresenter: Mariam Shalaby Session: Poster session 03 1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAEPresenter: Sarah Roffeis Session: Poster session 03 1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitorsPresenter: Antoine Italiano Session: Poster session 03 Resources: Abstract 1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signaturesPresenter: Elisabetta Nale Session: Poster session 03 1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based studyPresenter: Abdulrahman Alghabban Session: Poster session 03 1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatmentPresenter: Mariano Provencio Pulla Session: Poster session 03 1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancersPresenter: Annarita Avanzo Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|